On April 2, 2014 it was announced that AbCheck is now in a research collaboration with Pierre Fabre under which AbCheck will use its AbSieve discovery platform to deliver antibodies against targets provided by Pierre Fabre (External Source, Pierre Fabre, APR 2, 2014, View Source [SID:1234500363]). Pierre Fabre will have full rights to any antibodies selected and will make milestone payments and fees for discovery to AbCheck.
AbCheck says its AbSieve discovery platform combines its phage and yeast display technologies to develop antibodies in formats including full length IgGs as well as customer-specific and novel antibody formats. Its phage display libraries, according to the firm, allow for the discovery of specific high-affinity human antibodies for target proteins; the yeast display technology allows the selection of drug candidates with high affinities and improved drugability from a range of variants.
Previously this year, Pierre Fabre has entered two other cancer related agreements with Redx Pharma and Aurigene, respectively.